Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

D J Jonker; C S Karapetis; C Harbison; C J OCallaghan; D Tu; R J Simes; D P Malone; C Langer; N Tebbutt; T J Price; J Shapiro; L L Siu; R P W Wong; G Bjarnason; M J Moore; J R Zalcberg; S Khambata-Ford

首页> 外文期刊>British Journal of Cancer >Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

【24h】

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

机译：上皮调节蛋白基因表达作为西妥昔单抗治疗晚期大肠癌获益的生物标志物

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background:Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy–refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit.

机译：背景：抗EGFR抗体西妥昔单抗可改善K-ras野生型化疗难治性结直肠癌的总体生存率。表皮生长因子受体配体上皮调节蛋白（EREG）基因表达可能进一步预测西妥昔单抗的获益。

著录项

来源
《British Journal of Cancer》 |2014年第3期|共8页
作者
D J Jonker; C S Karapetis; C Harbison; C J OCallaghan; D Tu; R J Simes; D P Malone; C Langer; N Tebbutt; T J Price; J Shapiro; L L Siu; R P W Wong; G Bjarnason; M J Moore; J R Zalcberg; S Khambata-Ford;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer [J] . KubokiY., MatsusakaS., MinowaS., Anticancer Research: International Journal of Cancer Research and Treatment . 2013,第9期

机译：循环肿瘤细胞（CTC）计数和CTC上皮生长因子受体表达作为西妥昔单抗在晚期大肠癌中疗效的生物标志物
2. Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab [J] . Bart Jacobs, Wendy De Roock, Hubert Piessevaux Journal of Clinical Oncology . 2009,第30期

机译：西妥昔单抗治疗转移性结直肠癌的原发性肿瘤中双调蛋白和上调蛋白mRNA表达预测
3. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. [J] . Khambata-Ford S, Garrett CR, Meropol NJ, Journal of Clinical Oncology . 2007,第22期

机译：表皮调节蛋白和两性调节蛋白的表达以及K-ras突变状态预测了西妥昔单抗治疗的转移性结直肠癌患者的疾病控制。
4. MTA3 gene expression as potential gene biomarker for epithelial mesenchymal transition (EMT) study in colorectal cancer (CRC) cases [C] . Melati Putri Pertiwi, Dwi Listyorini, Hendra Susanto, International Conference on Biological Science . 2020

机译：MTA3基因表达作为潜在基因生物标志物用于上皮间充质转换（EMT）在结肠直肠癌（CRC）病例中的研究
5. Inflammation, Type 2 Diabetes, and Cancer: Identifying Biomarkers Associated with Colorectal Cancer and Type 2 Diabetes, and the Use of microRna Molecules as a Therapeutic Use for Cancer Treatment [D] . Guillen, Jenni. 2020

机译：炎症，2型糖尿病和癌症：鉴定与结肠直肠癌和2型糖尿病相关的生物标志物，以及使用MicroRNA分子作为癌症治疗的治疗用途
6. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer [O] . D J Jonker, C S Karapetis, C Harbison, 2014

机译：上皮调节蛋白基因表达作为西妥昔单抗治疗晚期大肠癌获益的生物标志物
7. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer [O] . Jonker D., Karapetis C., Harbison C., 2014

机译：上皮调节素基因表达作为西妥昔单抗治疗晚期结直肠癌的生物标志物

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅